Edesa Biotech, Inc. (EDSA) Research

Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.

Market snapshot

Symbol
EDSA
Price
$7.35
Day change
+6.83%
Market cap
$65.4M
P/E ratio
-5.81x
52-week range
0.72-20.32
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • BioRestorative Therapies, Inc. (BRTX)
  • Cocrystal Pharma, Inc. (COCP)
  • Dogwood Therapeutics, Inc. (DWTX)
  • Ernexa Therapeutics Inc. (ERNA)
  • Evogene Ltd. (EVGN)
  • Imunon, Inc. (IMNN)
  • Immuron Limited (IMRN)
  • OSR Holdings, Inc. (OSRH)

Recent insider activity

  • Nijhawan Pardeep — A-Award (153550 shares) on 2026-06-16
  • Nijhawan Pardeep — A-Award (1671 shares) on 2026-06-01
  • Marshall Patrick — A-Award (19000 shares) on 2026-05-27
  • MacDonald Sean Arthur — A-Award (19000 shares) on 2026-05-27
  • Chypyha Joan — A-Award (19000 shares) on 2026-05-27

Open Edesa Biotech, Inc. (EDSA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.